Abstract In human gliomas, the RTK/RAS/PI(3)K signaling pathway is nearly always altered. We present a model of experimental gliomagenesis that elucidates the contributions of genes involved in this pathway (PDGF-B ligand, HRAS-G12V, and AKT). We also examine the effect on gliomagenesis by the potential modifier gene, IDH1-R132H. Injections of lentiviral-encoded oncogenes induce de novo gliomas of varying penetrance, tumor progression, and histological grade depending on the specific oncogenes used. Our model mimics hallmark histological structures of high-grade glioma, such as pseudopalisades, glomeruloid microvascular proliferation, and diffuse tumor invasion. We use our model of gliomagenesis to test the efficacy of an experimental brain tumor gene therapy. Our model allowed us to test the contributions of oncogenes in the RTK/RAS/PI(3)K pathway, and their potential modification by over-expression of mutated IDH1, in glioma development and progression in rats. Our model constitutes a clinically relevant system to study gliomagenesis, the effects of modifier genes, and the efficacy of experimental therapeutics.
Introduction
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults, the incidence of which peaks between 45 and 75 years of age [1] . Despite recent advances in surgery and tumor-targeted radio-and chemotherapy, patients continue to succumb to this devastating disease within 18-21 months of initial diagnosis [2] . Novel therapies are desperately needed to extend significantly the overall survival of patients diagnosed with malignant glioma.
Traditional experimental rat glioma models utilize tumor cell lines established through the introduction of chemical carcinogens [3] [4] [5] [6] . Despite our reliance on these models over the last several decades, it is generally thought that brain tumors created in this way may not faithfully represent human gliomagenesis, as human brain tumor formation is thought to depend on specific genomic alterations. Models of gliomagenesis initiated by the introduction of gene-specific alterations through transgenic animals or viruses have been proposed as more representative model systems. These endogenous glioma models have been successful owing to the fact that these tumors display genetic heterogeneities and resemble human gliomas [7, 8] .
Whole-genome sequencing of human tumors has shown that high-grade gliomas are characterized by genetic alterations in three main pathways: i) the receptor tyrosine kinase (RTK)/rat sarcoma viral oncogene homolog (RAS)/phosphatidylinositol 3'-kinase (PI3K) signaling axis, which is associated with increased cell proliferation/protein translation; ii) the p14ARF/CDKN2A and TP53 signaling pathway, which is associated with loss of apoptotic control; and iii) the RB/ INK4a signaling pathway, which is associated with cell cycle progression [9, 10] . In adult human gliomas, RTK/RAS/PI3K signaling is altered in 88 % of tumors [11] . While many animal models have manipulated this pathway, the contributions of the individual oncogenes (PDGF-B ligand, HRAS-G12V, and AKT) have not been elucidated. Additionally, as the majority of low-grade gliomas and secondary glioblastomas carry a mutation in IDH1 (R132H) [12] [13] [14] , we wished to determine the contribution of this mutation to gliomagenesis.
Genetically engineered animal models of high-grade gliomas are helpful in understanding the role of genes mutated in human tumors, and provide a relevant platform upon which to screen new therapies. Transgenic rodents can be created with germline deletions in tumor suppressor genes or with the addition of oncogenes, either globally or in specific cell types. A challenge for these models is that induced mutations are expressed in all cells and tissues from early stages of development. However, human glioma formation is likely to be a stochastic event with mutations occurring in single cells, resulting in clonal expansion [15] .
To mimic human tumors, various systems have been developed to introduce somatic mutations into a restricted number of cells. For example, the Sleeping Beauty Transposon system has been used to stably incorporate oncogenes encoded on nonviral plasmids into the brains of newborn mice [16] . Other systems previously used to create endogenous gliomas include the RCAS/tv-a system in mice [17] , retroviral vectors in rats and mice [18] , and lentiviral vectors in mice [19] . Lentiviruses are ideally suited for the establishment of de novo gliomas owing to their ability to transduce both dividing and nondividing cells, and encoding large transgenic (>10 kb) DNA sequences, and have not been previously reported in rat models of glioma.
In this study, we achieved endogenous gliomas of varying penetrance, tumor progression, and histological grade using lentiviral vectors in adult rats, and elucidated the contributions of individual oncogenes and modifier genes in an animal model of human glioma.
Methods

Lentivirus and Adenovirus Production
We used fourth-generation, self-inactivating, replicationdeficient, VSV-G pseudotyped lentiviral vectors to induce gliomagenesis. The complementary DNA (cDNA) for human platelet-derived growth factor (PDGF)-β (PDGFB) was a kind gift from Dr. Eric Holland (Memorial Sloan-Kettering Cancer Center), while the cDNAs for constitutively active AKT and HRAS-G12V were kindly donated by Dr. Inder Verma (The Salk Institute for Biological Studies). Human IDH1 cDNA was purchased from Open Biosystems (Huntsville, AL, USA) with the IDH1-R132H point mutation being introduced using Stratagene's QuikChange II Sitedirected Mutagenesis Kit (Stratagene, La Jolla, CA, USA). cDNAs were subcloned into the lentiviral vector plasmids pLVX-Puro (Clontech, Mountain View, CA, USA) and pLVX-Puro-IRES-mCitrine to make the plasmids pLVXPuro-PDGFB, pLVX-Puro-AKT, pLVX-Puro-HRAS-G12V, pLVX-Puro-IDH1-IRES-mCitrine, and pLVXPuro-IDH1-R132H-IRES-mCitrine, all under the control of the major immediate early human cytomegalovirus promoter (see Supplementary Fig. 1 for gene construct details). Lentiviral vectors were rescued by cotransfection with Packing Mix (Clontech) into 293-TX cells (Clontech), according to the manufacturer's instructions. After 3 days, cell culture supernatant containing lentiviral particles was collected and concentrated by ultracentrifugation. Infectious lentiviral titers were determined by end-point dilution on HT1080 cells (Clontech) followed by puromycin selection. One week later, cresyl violet staining was used to quantify puromycinresistant colonies to determine the lentiviral titer. All viral preparations exhibited undetectable levels of replicationcompetent lentivirus and lipopolysaccharide contamination. Treatment of high-grade gliomas was performed using firstgeneration adenovirus (serotype-5) expressing herpes simplex virus type 1-thymidine kinase (Ad-TK). The adenovirus was generated using a previously described method [20] .
Animal Studies
Seven-to-10-week-old adult Sprague Dawley rats (Harlan, Indianapolis, IN, USA) weighing 180-220 g were used in the experiments. All animal studies were conducted according to the guidelines approved by the University Committee on Use and Care of Animals at the University of Michigan. Endogenous gliomas were generated by intracranial injections of various combinations of lentivirus expressing PDGFB, HRAS-G12V, and/or AKT at a volume of 1 μl per lentiviral vector delivered in a total volume of 3 μl using 0.9 % saline as a carrier solution. For survival studies, animals were monitored daily for signs of morbidity, including ataxia, impaired mobility, hunched posture, seizures, and nasal/periorbital hemorrhage. Animals displaying symptoms of morbidity were perfused by intracardial perfusion of Tyrode's solution, followed with fixation using 4 % paraformaldehyde in phosphate buffered saline. Rat brains were then removed from the skull and processed for histology. Tumor progression was assessed by sacrificing rats and determining tumor size on days 7, 14, 21, and 28 post-lentiviral injection.
PDGF-β protein secretion was confirmed by enzymelinked immunosorbent assay, while Flag-tagged HRAS-G12V and HA-tagged AKT protein expression were confirmed using immunohistochemistry against their respective tags. IDH1 and IDH1-R132H protein expression was confirmed via Western blot and immunohistochemistry using anti-IDH1 primary antibodies or primary antibodies specifically recognizing the sequence of amino acids involving the IDH1-R132H point mutation, a kind gift from Dr Von Deimling (German Cancer Research Center) (see Supplementary Table 1 for antibody details) [21] .
Animals receiving gene therapy were given intracranial injections of 3 μl of Ad-TK (or normal saline as a control) on day 14 or 23 post-lentivirus injection using the same coordinates and burr hole used to establish the tumor. Beginning 24 h post-Ad-TK treatment, animals were administered, intraperitoneally with ganciclovir (Roche, San Francisco, CA, USA) at a dose of 25 μg/kg twice daily for 1 or 3 cycles on 10 consecutive days.
In vivo Stereotactic Lentiviral Vector Injection
We have previously described a detailed methodology for stereotactic gene transfer into the rat brain [22] . Briefly, following anesthesia, rat's crania were secured using a stereotactic frame. A midline incision was then made over the cranium and a burr hole was made 2.0 mm lateral and 2.5 mm rostral relative to the bregma. A total volume of 3 μl lentiviral particles was then delivered at 3 depths from the surface of the brain (3.0, 3.5, and 4.0 mm ventral), with 1 μl of the total volume of 3 μl being delivered at each depth. All lentiviral injections were made at a flow rate of 0.2 μl per min. The same coordinates and total volume were used when delivering adenoviral particles for gene therapy.
Cell Culture and Transfection 293 T cells were cultured in Dulbecco's modified Eagle's medium (Gibco, Carlsbad, CA, USA) with 10 % heatinactivated fetal bovine serum, 0.3 mg/ml L-glutamine, and 50 U/ml penicillin and 50 μg/ml streptomycin. For expression of wildtype and mutant IDH1, 293 T cells were transfected with either pLVX-Puro-IDH1-IRES-mCitrine or pLVXPuro-IDH1-R132H-IRES-mCitrine, respectively, using the JetPrime (Polyplus-transfection Inc., New York, NY, USA) transfection reagent according to manufacturer's instructions, with the exception that transfection mix was added to cells in suspension prior to plating.
Immunohistochemistry and Cresyl Violet (Nissl) Staining
Rat brains were fixed in 4 % paraformaldehyde for an additional 48 h at 4°C prior to sectioning using a vibratome set to 60 μm in the z-direction. Both cresyl violet and immunebased staining of brain tissue sections were performed using previously described standard protocols (see Supplementary  Table 1 for a full list of antibodies and their dilutions) [22] .
Microscopic Analysis
Images were obtained using brightfield/epifluorescence (Zeiss Axioplan 2; Carl Zeiss MicroImaging, Jena, Germany), or laser scanning confocal microscopy (Leica DMIRE2; Leica Microsystems, Buffalo Grove, IL, USA) and analyzed using LSM5 software (Carl Zeiss MicroImaging). Tumor volume and stereological quantification of Ki67 + cells were done using StereoInvestigator software (Microbrightfield, Williston, VT, USA). To measure tumor volume, every ninth serial brain section was selected. Throughout the enter rat brain. These sections were then stained with cresyl violet to visualize gross micoanatomical features. The tumor mass was measured using point counting at low magnification (1.25× objective), and the volume was determined using the Cavalieri estimator at a grid size of 100 μm. To quantify the number of proliferating cells, 3 sections representing the anterior, middle, and posterior aspects of the tumor were randomly selected and immunolabeled for Ki67. The tumor border was initially delineated using low magnification, followed by quantification of Ki67 + cells in 10 random 150-μm square grids using high magnification (40× objective). Data were reported as the average number of Ki67 + cells per 10 high magnification fields of view.
Statistical Analysis
Kaplan-Meier survival curves were statistically analyzed using the Mantel-Cox log-rank method as performed by GraphPad Prism software (GraphPad, San Diego, CA, USA). Differences in tumor volume were statistically analyzed using one-way analysis of variance followed by Tukey's post-tests using NCSS statistical and power analysis software (NCSS, East Kaysville, UT, USA). Differences were considered significant at the p<0.05 level.
Results
The Combination of HRAS-G12V and PDGFB Creates De Novo Gliomas with Rapid Tumor Progression, Full Penetrance, and High-grade Histology
We used various combinations of lentiviral vectors encoding proto-oncogenes (i.e., PDGFB and IDH1); constitutively active oncogeneic mutants (HRAS-G12V, AKT); and an overexpressed modifier gene (IDH1-R132H) ( Supplementary  Fig. 1 ) to assess their ability to induce de novo gliomas. Tumor-related morbidity was variable and depended on the specific combination of lentiviral vectors used (Fig. 1 , Table 1 ). Animals injected with combinations of lentivirus containing HRAS-G12V and PDGFB achieved fully penetrant tumors of high-grade histology and rapid tumor progression. Gliomas induced with the combination of HRAS-G12V/PDGFB/AKT displayed all the hallmarks of human GBM, including necrotic regions surrounded by pseudopalisading tumor cells, glomeruloid microvasculature proliferation, high proliferation index, and diffuse tumor invasion ( Fig. 1C-P) .
Analysis of high-grade gliomas induced by the combination of (HRAS-G12V/PDGFB/AKT) indicated that lentiviral vectors were capable of infecting a wide-range of cell-types, including astrocytes, oligodendrocytes, endothelial cells, and microglia ( Supplementary Fig. 2 ). As the majority of tumor cells in these high-grade tumors were Nestin-, Olig2-, and Vimentin-positive, it suggests that these tumors were derived from oligodendrocyte and/or astrocyte precursor populations; nevertheless, definite classification of the lineage leading to these high grade gliomas will require further detailed lineage tracing studies.
PDGFB Hastens Tumor Progression of HRAS-G12V-induced Gliomas
Animals injected with combinations of lentivirus containing HRAS-G12V, in the absence of PDGFB (i.e., HRAS-G12V alone; HRAS-G12V/AKT; HRASG12V/IDH-R132H; HRAS-G12V/AKT/IDHR-132H) achieved gliomas in~75 % of rats, except for the combination of HRASG12V/AKT (Fig. 1A, B) , suggesting that HRAS-G12V alone is sufficient for de novo tumor formation. However, in the absence of PDGFB gene expression, the time to tumor progression was substantially extended by approximately 6 months. Gliomas derived from lentivirus encoding HRAS-G12V (with or without AKT)
showed variability in histological grade, exhibiting both low-and high-grade tumors (Table 1A) . Low-grade gliomas resulting from injection of HRAS-G12V/AKT were characterized by nuclear atypia, low levels of mitosis, and moderate endothelial proliferation, but lacked the hallmark features of high-grade tumors (Table 1B) . These tumors also exhibited the predilection of Vimentin + and Nestin + cells to localize around neurovasculature both within the tumor center and at the periphery, where tumor cells infiltrated the normal brain (Fig. 2) .
PDGFB expression hastened the progression of glioma formation, as each lentiviral combination with HRAS-G12V in the absence of PDGFB created tumors that were less penetrant than those expressing PDGFB. However, despite this fact, HRAS-G12V-derived gliomas did show the hallmark signs of high-grade pathology, including pseudopalisading cells, glomeruloid microvasculature, and vasculatureassociated thrombus.
IHD1-R132H does not Alter De Novo Glioma Induction or Progression
We found no significant difference between animals injected with IDH1 or IDH1-R132H in terms of tumor penetrance or tumor progression (Fig. 1B, Supplementary  Table 2 ). In the absence of clinical signs we examined brains of non-symptomatic animals at 6 months infected with PDGFB/IDH1-R132H (n=6) and AKT/IDH1-R132H (n=4), and found no evidence of small-or lower-grade glial tumors. We validated IDH1-R132H vector expression in vitro using Western blot, and in situ using immunohistochemisty. Both methods confirmed the hypermethylated phenotype given by the IDH1-R132H point mutation ( Supplementary Fig. 1D, E) .
A Detailed Investigation of Pseudopalisade Formation and Tumor Infiltration in High-grade De Novo Gliomas
The near ubiquitous presence of pseudopalisades within gliomas induced with the combination of HRAS-G12V/PDGFB/ AKT allowed for a detailed investigation of their cytology, growth, and interaction with surrounding normal brain tissue (Fig. 3) . Pseudopalisade centers found within these tumors were predominantly necrotic with few remaining cells expressing HRAS-G12V and AKT protein, Nestin, and Vimentin ( Supplementary Fig. 1B ). Nestin-positive/ Vimentin-positive (i.e., tumor) cells also constituted the majority of cells in the high-density ring of each pseudopalisade (Fig. 3A-C) . Glial fibrillary acidic protein-and myelin basic protein-positive cells were invariably found outside palisading tumor cells, neuronal nuclei (NeuN)-positive neurons were also distant from these structures (Fig. 3D, E) .
We sought to demonstrate the degree of infiltration in HRAS-G12V/PDGFB/AKT gliomas using Vimentin, an (Fig. 4) . Tuj1 and NeuN immunolabeled brain tissue sections revealed bundles of neuronal axons trapped between tumor cells in the central areas of the tumor mass (Fig. 4D, E) , suggesting the existence of a larger area of tissue invasion. Table 1 Summary of the tumor progression, penetrance, and neuropathology of de novo gliomas. (A) Tumors resulting from combinations of lentiviral vectors encoding HRAS-G12V and PDGFB exhibit full penetrance, rapid tumor progression, and high-grade histology, while tumors resulting from lentiviral vectors encoding HRAS-G12V, in the absence of PDGFB, are of mixed grade, show high penetrance, but have slower tumor progression (approximately 6 months from the time of lentivirus injection). Tumors resulting from lentiviral vectors encoding PDGFB, in the absence of HRAS-G12V have low penetrance, with slow tumor progression, yet are of high-grade histology. (B) Patterns of histology seen in the tumor models from (A). The most aggressive histology is seen when HRAS-G12V and PDGFB are combined (first column in red). These high-grade gliomas form pseudopalisades with high frequency. HRAS-G12V models, without PDGFB, develop with high frequency, but less malignant behavior, either with (high-grade, green column) or without (low-grade, blue column) necrosis/pseudopalisades. Interestingly, thrombus formation was only seen in high-grade HRAS-G12V in the absence of PDGFB
The Response to Adenoviral-mediated Gene Therapy in High-grade De Novo Glioma is Dependent on the Extent of Tumor Burden
Taking advantage of the complete penetrance and the rapid and predictable tumor development of the HRAS-G12V/PDGFB/AKT-induced high-grade gliomas, we performed a time course analysis of high-grade tumor progression. We investigated histology and tumor volumes at 7-, 14-, 21-, and 28-days post-lentiviral injection to track tumor progression and pathology (Fig. 5) . The greatest increase in tumor growth occurred between days 21 and 28 post-lentiviral injection, at which point all of the features of stage IV GBM were present (Fig. 5A, B) .
We treated these high-grade gliomas either at early time points in their development, before pseudopalisade formation, or late in their development, after the formation of these structures, with Ad-TK adenoviral-mediated, conditionally cytotoxic, gene therapy. Rat survival rate significantly improved when treated at day 14 post-lentiviral injection (Fig. 5C) . However, survival rates were similar to controls when rats were treated at day 23 post-injection, corresponding to larger tumor burden (Fig. 5D ).
Discussion
Using lentiviral vectors stereotactically injected into the striata of adult Sprague Dawley rats, we elucidated the individual contributions of oncogenes that mimic the oncogenic pathway activation in human malignant gliomas. In our model, within the RTK/RAS/PI(3)K pathway, HRAS-G12V gave the highest penetrance of glial tumors; PDGFB had low penetrance, but increased penetrance and tumor grade in combination with other oncogenes; and AKT had little-to-no impact on tumor progression or penetrance. Using this model system, we failed to detect an effect of IDH1-R132H point mutation on glioma penetrance or tumor progression. The predictable tumor growth afforded by the combination of HRAS-G12V/ PDGFB allowed us to assess an experimental antiglioma therapy against malignant gliomas during early and late stages of growth. This model will serve as a robust platform to begin assessment of the efficacies of other novel antiglioma therapeutics.
Previous animal models (Table 2) have been built on manipulations of the RTK/PI3K/HRAS-G12V (i.e., proliferative) signaling pathway in order to reliably create tumors in mice and rats [17] [18] [19] [23] [24] [25] [26] [27] [28] . In previous animal models, while deletion of PTEN is clearly an important driver, addition of oncogenic AKT and RAS are frequently required in combination with each other or with alterations p53 or RB signaling for tumor formation. In our model, in the presence of wildtype p53, RAS was sufficient to generate highly penetrant gliomas. Within this pathway, PDGF-B ligand plays an important role, and is sufficient to form high-grade gliomas, albeit with a wide range of penetrance and clinical course when used individually [17, 18, 23] . Our results indicate that while PDGFB alone is sufficient to create high-grade gliomas, tumor penetrance is low. The combination of PDGFB with lentiviruses expressing HRAS-G12V increased tumor penetrance, hastened tumor progression, and induced uniformly malignant high-grade gliomas. Of all oncogenes tested, HRAS-G12V was the most consistent in driving gliomagenesis, although tumor progression was substantially protracted compared with gliomas induced with the combination of HRAS-G12Vand PDGFB. Our work demonstrates that gliomagenesis in rats is dependent on the activation of signaling pathways stimulated by HRAS-G12V and PDGFB. Conversely, AKT had far less of an effect on tumor development and progression than has been described previously [19, 26] . In the study by Marumoto et al. [19] , the combination of lentiviral HRAS-G12V with AKT was required to produce highly penetrant gliomas in mice [19] . Possible reasons for this discrepancy are either species differences (highly penetrant gliomas were induced in wildtype P53 rats), location of viral injections [subventricular zone and hippocampus in mice [19] vs striatum in rats (this study)], or cell of origin of glioma. In rats, low-volume injections were carefully placed in the striatum, reducing any chances of diffusion to the subventricular zone or hippocampus.
The choice of rodent species determines significant differences in the capacity to develop high-grade gliomas of high penetrance and short latency. In order to reach these practical goals for de novo glioma modeling in mice, genetic alterations decreasing the efficacy of the TP53 and RB tumor suppressor genes have been necessary [16, 17, 23, 25, 27, 28] . In rats, our data confirm the results of Assanah et al. [18] , suggesting that the need for p53 inactivation in glioma may be speciesdependent, and that the manipulation of the RTK/RAS/ PI(3)K signaling pathway is sufficient to create gliomas in rats. There is evidence that neurogenesis in rats is higher than in mice, which might explain the increased tumorigenic response to manipulations of oncogenes in the proliferation pathways [29] .
Human gliomas are genetically heterogeneous, and whether all mutations are required to be present in the same tumor cell or not remains to be determined. If we assume that noncell autonomous mutations must coexist in the same cell, one would need to show such coexistence at the time of infection and during tumor development. Owing to technical limitations we were unable to determine if individual cells were, indeed, coinfected in our tumors. Nevertheless, as PDGFB is secreted, its cooperativity with other cell-autonomous oncogenes is less dependent on coexpression in the same glioma cells. We tested whether expression of glioma-associated IDH1-R132H contributes to tumor formation in rats. We failed to detect an effect of IDH1-R132H point mutation on glioma penetrance or tumor progression in our model. A potential limitation of our interpretation is that even though we showed biological effects of IDH1-R132H on histone methylation in vitro (suggested to contribute to oncogenesis in human glioblastoma [30] ), we have yet to confirm similar biological effects in the gliomas in rats. The absence of effects of IDH1-R132H in our experiments could, potentially, be explained by functional differences in the activity of IDH1 in rodents and humans [31] . Alternatively, recent clinical trial data in human patients show that IDH1-R132H, in addition to previously identified 1p19q loss of heterozygosity, substantially increases the response of adult glioma to treatment [32, 33] . If the main role of IDH1-R132H is to increase sensitivity to treatments, we would not predict seeing a direct influence on glioma formation in our untreated rodents. Regardless, further studies of the biological function of the IDH1-R132H mutation in animal models of glioma are warranted to help elucidate its contribution to gliomagenesis.
For models to be relevant for human GBM they need to replicate both the genetic changes and the histopathology of the human disease. Though not required for a pathological diagnosis, pseudopalisades are highly specific to glioblastoma, and consist of a hypercellular ring surrounding a predominantly necrotic core [34] . Previous papers have suggested that pseudopalisades are a highly mobile population of cells fleeing an area of hypoxia caused by thrombosed vessels [34] . Using our HRAS-G12V/PDGFB/AKT model, we performed a detailed investigation of pseudopalisade formation and the infiltrative capacity of high-grade gliomas. Contrary to previous observations, we failed to detect thrombosed vessels within the core of pseudopalisades. Notably, few neurons remain in the tumor area rich in pseudopalisades. This may indicate that pseudopalisades form late during tumor growth, once normal brain tissue has been effaced.
Treatment of HRAS-G12V/PDGFB/AKT tumors with the combination of Ad-TK and systemic ganciclovir was effective if administered at early time points, corresponding to low tumor burden. However, if tumors were left untreated until tumor burden was large, the therapy failed. This experiment demonstrates the utility of our endogenous glioma model as a platform for the testing of preclinical therapeutics.
Our work provides insight into the biogenesis and maturation of pseudopalisades, the identification of substantial invasion of normal brain tissue, and the contribution of individual genes to the formation of high-and low-grade gliomas. Furthermore, we demonstrate that this model can be used to test the pathogenic role of further mutations, such as those described in IDH1. With the availability of accurate, consistent, and robust preclinical animal models with high penetrance and predictable course of tumor progression, we will be able to test novel therapeutic approaches to combat this lethal disease.
